The Times Australia
Google AI
PR Newswire

.

Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform-PR Newswire APAC

Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform-PR Newswire APAC

HYDERABAD, India and CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Excelra[1], a leading global data science & data analytics company, and Cellarity, a flagship pioneering company working on the development of a new generation of medicines to treat diseases at the level of cell behaviours, have today announced an agreement whereby Excelra will provide Cellarity access to its Global Online Structure Activity Relationship database (GOSTAR).

GOSTAR[2] is the world's largest small molecule medicinal chemistry intelligence platform that encompasses over 8 million compounds, linking chemical structure to biological, pharmacological and therapeutic activities. With a vast knowledge base of 28 million SAR data points, GOSTAR equips researchers in the early as well as optimization stages of drug discovery.

Cellarity's drug discovery platform uses high-resolution biological data and unique machine learning capabilities to pioneer an entirely new approach to drug discovery. Cellarity is designing medicines that target and change cell behaviors to unlock treatments in a large number of disease areas. "We are looking forward to using high quality annotated GOSTAR data on millions of small molecules, while leveraging Cellarity's proprietary AI/ML modules to generate predictable drug-like molecules that ultimately guide the design of novel Cell Behavior-Targeted therapies. Our preliminary assessment gives us the confidence in the utility of GOSTAR database," said Ramakanth Sarabu, Head of Chemistry, Cellarity.

"GOSTAR is a widely used structure activity relationship database in AI/ML driven drug discovery programs. We strongly believe that this collaboration equips AI/ML and medicinal chemistry researchers at Cellarity to utilize curated interactions of millions of small molecules with potential drug targets to generate novel compounds with desired pharmacological profiles," said Raveendra Dayam, Director, Chemistry Services, Excelra.

About Cellarity:

Cellarity is a first-of-its-kind therapeutics company that is discovering and developing medicines by studying and altering cell behaviors. Cellarity has developed a powerful, generalizable platform harnessing single-cell technologies, machine learning and proprietary data models of disease to unveil the network state of a given cell. The platform digitizes and quantifies cellular behaviors, unravels the network dynamics that govern those behaviors, and generates medicines that can direct them. https://cellarity.com/[3]

About Excelra:

Excelra's data science and data analytics solutions empower innovation in life sciences. The Excelra Edge comes from a seamless amalgamation of proprietary data assets, domain expertise and data science to accelerate drug discovery & development. Visit www.excelra.com[4]

Contact: Dorothy Paul- Director Marketingdorothy.paul@excelra.com[5] 

 

References

  1. ^ Excelra (www.excelra.com)
  2. ^ GOSTAR (www.excelra.com)
  3. ^ https://cellarity.com/ (cellarity.com)
  4. ^ www.excelra.com (www.excelra.com)
  5. ^ dorothy.paul@excelra.com (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/3179526_AE79526_0

Business Times

Mint Payments partners with Zip Co to add flexible payment option…

Mint Payments, Australia's leading travel payments specialist, today announced a partnership with Zip Co (ASX: ZIP), a digi...

When Holiday Small Talk Hurts Inclusion at Work

Dr. Tatiana Andreeva, Associate Professor in Management and Organisational Behaviour, Maynooth University, Ireland, tatia...

Reflections invests almost $1 million in Tumut River park to boos…

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched four tiny homes at its Tu...

The Times Features

I’m heading overseas. Do I really need travel vaccines?

Australia is in its busiest month[1] for short-term overseas travel. And there are so many thi...

Mint Payments partners with Zip Co to add flexible payment options for travel merchants

Mint Payments, Australia's leading travel payments specialist, today announced a partnership with ...

When Holiday Small Talk Hurts Inclusion at Work

Dr. Tatiana Andreeva, Associate Professor in Management and Organisational Behaviour, Maynooth U...

Human Rights Day: The Right to Shelter Isn’t Optional

It is World Human Rights Day this week. Across Australia, politicians read declarations and clai...

In awkward timing, government ends energy rebate as it defends Wells’ spendathon

There are two glaring lessons for politicians from the Anika Wells’ entitlements affair. First...

Australia’s Coffee Culture Faces an Afternoon Rethink as New Research Reveals a Surprising Blind Spot

Australia’s celebrated coffee culture may be world‑class in the morning, but new research* sugge...

Reflections invests almost $1 million in Tumut River park to boost regional tourism

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched ...

Groundbreaking Trial: Fish Oil Slashes Heart Complications in Dialysis Patients

A significant development for patients undergoing dialysis for kidney failure—a group with an except...

Worried after sunscreen recalls? Here’s how to choose a safe one

Most of us know sunscreen is a key way[1] to protect areas of our skin not easily covered by c...